Black Diamond Therapeutics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

Rhea-AI Summary

Black Diamond Therapeutics, a precision oncology medicine company, announced that its CEO, David M. Epstein, will present an update on the company's advancements at the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1-3, 2020. The presentation will be available via webcast starting at the conference's beginning and archived for three weeks on the company’s investor relations website. Black Diamond integrates its proprietary Mutation-Allostery-Pharmacology platform to discover small molecule therapies targeting genetically defined cancers.

CAMBRIDGE, Mass. and NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update about the Company’s progress at the Piper Sandler 32^nd Annual Virtual Healthcare Conference, taking place December 1-3, 2020.

A webcast of the presentation will be made available at the start of the conference on the investor relations section of the Company’s website, www.blackdiamondtherapeutics.com. A replay of the presentation will also be available and archived on the site for three weeks.  

About Black Diamond
Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of small molecule, tumor-agnostic therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. The Company’s proprietary technology platform, Mutation-Allostery-Pharmacology (MAP) platform, is designed to allow Black Diamond to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families, and develop a single small molecule therapy in a tumor-agnostic manner that targets a specific family of mutations. Black Diamond was founded by David M. Epstein, Ph.D. and Elizabeth Buck, Ph.D., and, beginning in 2017, together with Versant Ventures, began building the MAP platform and chemistry discovery engine. For more information, please visit www.blackdiamondtherapeutics.com.

Contacts:

For Investors:
Natalie Wildenradt
investors@bdtherapeutics.com

For Media:
Kathy Vincent
(310) 403-8951
media@bdtherapeutics.com

FAQ

When is the Piper Sandler Virtual Healthcare Conference for BDTX?

The Piper Sandler 32nd Annual Virtual Healthcare Conference for Black Diamond Therapeutics (BDTX) will be held from December 1-3, 2020.

Who is presenting for BDTX at the conference?

David M. Epstein, Ph.D., the President and CEO of Black Diamond Therapeutics, will present at the conference.

Where can I watch the BDTX presentation from the conference?

The BDTX presentation can be watched via webcast, available on the investor relations section of the company's website.

How long will the BDTX presentation be available for replay?

The replay of the BDTX presentation will be available and archived on the website for three weeks after the conference.

What is the focus of Black Diamond Therapeutics?

Black Diamond Therapeutics focuses on developing small molecule, tumor-agnostic therapies for genetically defined cancers.